Regulatory issues in the era of highly active antiretroviral therapy.
Murray
J S
JS
Division of Antiviral Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA.
D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D012107:Research Design / Q000592:standards*; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013810:Therapeutic Equivalency
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors